Skip directly to content

XELJANZ®▼ (tofacitinib citrate)

XELJANZ is a medicine that contains the active substance tofacitinib. Tofacitinib is a small molecule which blocks the activity of a protein inside human cells which can cause inflammation.

XELJANZ is used to treat adult patients with moderate to severe active rheumatoid arthritis (RA), a long-term disease that mainly causes pain and swelling of your joints. 

XELJANZ is used together with methotrexate when previous rheumatoid arthritis treatment was not sufficient or was not well tolerated. XELJANZ can also be taken on its own in those cases where methotrexate treatment is not tolerated or treatment with methotrexate is not advised.

XELJANZ can reduce pain and swelling of the joints and can improve the ability to perform daily activities when given on its own, or together with methotrexate. 

XELJANZ is a 5mg tablet for oral use. Treatment should be supervised by a specialised doctor who knows how to treat arthritis conditions.

The medicine can only be obtained with a prescription.

If you would like to see the Patient Information Leaflet (PIL) or Summary of Product Characteristics (SPC) for XELJANZ these can be found at the electronic Medicines Compendium (eMC).

 

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professionals for specific, health-related advice and support.

PP-XEL-GBR-0659 / Oct 2017